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SUMMARY 
 
Sjögren’s syndrom (SS) is an autoimmune, chronic inflammatory disorder predominantly 
affecting the salivary and lacrimal glands. The overall aim of this study was to determine 
clinicopathological features in human and murine disease with regard to organization of 
ectopic lymphoid tissue, and to explore possible strategies for detection of patients at 
increased risk for extra-glandular manifestations. 
 
Mononuclear cell infiltrates in the shape of germinal centers (GC) were observed in the 
salivary glands of approximately 1/4th of patients. Phenotypic markers for GC components 
such as T and B cells, proliferating cells, follicular dendritic cells and plasma cells confirmed 
the ectopic GC formation. The pattern and distribution of homing and retentive chemokines 
CXCL12, CXCL13 and CCL21, and adhesion molecules/integrin pairs ICAM/LFA and 
VCAM/VLA, was described in various lymphoid organizations in minor salivary glands. In 
addition, local autoantibody production was detected and correlated with serum levels. 
 
Focal infiltrates and GC could be observed within the same gland, and were separated by 
altered B and T cell ratios, higher degree of proliferation and the localization of plasma cells 
in the periphery of infiltrates. Serum levels of BAFF and APRIL were elevated in pSS, and 
were in part linked to focus score, elevated serum IgG and autoantibody levels. 
 
In a large cohort of pSS, ectopic GC were also associated with higher focus scores, lower 
mean un-stimulated salivary secretion, Ro/SSA and La/SSB autoantibodies, elevated RF-titres 
and increased serum IgG. Not all morphological GC could be confirmed by 
CD21/CD23/CD35 labeling, but clinical features remained comparable. 
 
E-cadherin, an adhesion molecule important for epithelial tissue integrity, was investigated in 
minor salivary glands. E-cadherin is the ligand of integrin αEβ7/CD103 and lymphocytes 
expressing this integrin were increased in SS compared to non-SS. E-cadherin+ infiltrating 
cells were identified as CD68+ macrophages. Serum levels of sE-cadherin were increased in 
pSS compared to healthy blood donors and most likely mirror the chronic inflammatory state. 
 
The non-obese diabetic (NOD) mouse is an animal model of SS. We observed significant 
changes in inflammation between 8 and 17 weeks of age, while hyposalivation was first 
observed between 17 and 24 weeks. In 1/3rd of mice older than 17 weeks, proliferating cells 
were observed in the focal infiltrates. Significant differences were detected in serum cytokine 
levels of IL-2, IL-5 and GM-CSF, and IL-4 and TNF-α in saliva. Salivary secretion correlated 
with IL-4, IFN-γ and TNF-α levels in saliva of NOD mice, but not with inflammatory 
changes in the salivary glands. Focal sialadenitis preceded hyposalivation, which occurred 
without a significant change in inflammation in NOD mice. Proliferating inflammatory cells 
indicate contribution of local factors in progression of SS-like disease. 
 
In conclusion, ectopic germinal centers occur in a sub-group of patients with SS and are 
characterized by autoantibody production, progressive disease and increased serum IgG. It 
remains unclear whether the observed GC are a result of long-standing inflammation or 
indeed have functional properties and thus play an active role in the pathogenesis. A future 
challenge will be to identify and target trafficking molecules which drive the chronic 
inflammation in SS, without affecting migration and function of leukocytes required for 
protective immunity. 
 4
TABLE OF CONTENTS 
 
SUMMARY  ……………………………………………………………… 3 
LIST OF PAPERS ……………………………………………………………… 5 
ABBREVIATIONS ……………………………………………………………… 6 
INTRODUCTION …………………………………………………………….. . 7 
GENERAL BACKGROUND ……………………………………………… 7 
Immunology of mucosa ……………………………………………… 7 
Mediators of the immune system ……………………………………… 8 
 Cytokines ……………………………………………………… 8 
 Chemokines ……………………………………………………… 10 
 Adhesion molecules ……………………………………………… 10 
Autoimmunity ……………………………………………………… 12 
 Immunological tolerance ……………………………………… 12 
 Mechanisms of autoimmunity ……………………………………… 13 
 The clinical aspect of autoimmunity ……………………………… 13 
SJÖGREN’S SYNDROME ……………………………………………………… 16 
 Disease manifestations ……………………………………………… 16 
Clinical symptoms ……………………………………………… 16 
Histopathology of the target organ ………………………………. 16 
Serology ……………………………………………………… 17 
Etiology and pathogenesis ………………………………………………. 17 
 Early inflammatory events ……………………………….……….... 17 
  Ectopic germinal centers ………………………………………. 20 
 Lymphoid malignancy ………………………………………. 20 
Animal models of SS ……………………………………………………… 21 
 NOD ……………………………………………………………… 21 
AIMS OF THE STUDY ……………………………………………………… 22 
OVERVIEW OF PAPERS I-IV ……………………………………………… 23 
MATERIALS AND METHODS ……………………………………………… 25 
OVERVIEW OF PAPER V ……………………………………………………… 26 
SUMMARY OF RESULTS ……………………………………………………… 35 
GENERAL DISCUSSION ……………………………………………………… 37 
CONCLUSIONS ……………………………………………………………… 49 
FUTURE PROSPECTIVES ……………………………………………………… 50 
ACKNOWLEDGEMENTS ……………………………………………………… 52 
REFERENCES ……………………………………………………………… 54 
ERRATA ……………………………………………………………………… 63 
PAPERS I-V ……………………………………………………………………… 64
 5
LIST OF PAPERS 
 
This thesis is based on the following papers, which will be referred to in the text by their 
Roman numerals: 
 
I. Salomonsson S, Jonsson MV, Skarstein K, Hjälmström P, Wahren-Herlenius M, 
Jonsson R. Cellular basis of ectopic germinal center formation and autoantibody 
production in the target organ of patients with Sjögren’s syndrome. Arthritis & 
Rheumatism 2003;48(11):3187-201. 
 
II. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between 
circulating levels of the novel TNF family members APRIL and BAFF and lymphoid 
organization in primary Sjögren’s syndrome. Journal of Clinical Immunology, 
2005;25(3):189-201. 
 
III. Jonsson MV, Skarstein K, Jonsson R, Brun JG. Germinal centers in primary 
Sjögren’s syndrome indicate a certain clinical immunological phenotype. Submitted. 
 
IV. Jonsson MV, Salomonsson S, Gunnvor Øijordsbakken, Skarstein K. Elevated serum 
levels of soluble E-cadherin in patients with primary Sjögren’s syndrome. 
Scandinavian Journal of Immunology, 2005;62(6):552-9. 
 
V. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary 
gland function in NOD mice – association with changes in cytokine profile but not 
with salivary gland histopathology. Arthritis & Rheumatism, in press. 
 
 
 
 
 
 
 
 
 
Approval to reproduce papers was obtained from the publishers.
 6
ABBREVIATIONS 
 
ABC   avidin-biotin-peroxidase complex 
ANA   antinuclear antibodies 
APC   antigen presenting cell 
APRIL  A Proliferation Inducing Ligand 
AQP   aquaporin 
BAFF/BLyS  B cell Activating Factor/B Lymphocyte Stimulator 
BCA-1  B cell Attracting chemokine-1/CXCL13    
BCR   B cell receptor 
CD   clusters of differentiation 
DNA   deoxyribonucleic acid 
sE-cadherin  soluble E-cadherin 
ELISA   enzyme-linked immunosorbent assay 
FasL   Fas ligand 
FasR   Fas receptor 
FDC   follicular dendritic cell 
FI   focal infiltrate 
GC   germinal center 
GlyCAM-1  glycosylation-dependent cell adhesion molecule-1 
H&E   haematoxylin and eosin 
HEV   high endothelial venule 
HLA   human leukocyte antigen 
ICAM-1  intercellular adhesion molecule-1 (CD54)  
IDDM   insulin-dependent diabetes mellitus 
IFN   interferon 
Ig   immunoglobulin 
IL   interleukin 
kD   kilo Dalton 
LFA-1   lymphocyte function associated antigen-1 (CD11a) 
MAdCAM-1  mucosal addresin cell adhesion molecule-1 
MALT   mucosa associated lymphoid tissue 
MHC   major histocompatibility complex 
NHBCL  non-Hodgkins B cell lymphoma 
PNAd   peripheral node addressin 
RNA   ribonucleic acid 
NOD   non-obese diabetic 
RA   rheumatoid arthritis 
RF   rheumatoid factor 
SDF-1   stromal cell-derived factor-1 (CXCL12) 
SLC   secondary lymphoid tissue chemokine (CCL21) 
SLE   systemic lupus erythematosus 
SS   Sjögren’s syndrome 
TCR   T cell receptor 
TGF   transforming growth factor 
TNF   tumor necrosis factor 
TUNEL terminal deoxynucleotidyl transferase mediated dUTP digoxigenin nick 
end labelling 
VCAM-1  vascular cell adhesion molecule-1 (CD106) 
VLA-4  very late activation antigen-4 (CD49d) 
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INTRODUCTION 
Sjögren’s syndrome (SS) is a systemic autoimmune disease with organ-specific features. 
Autoimmune diseases are thought to result from a loss of immunological self-tolerance, 
leading to immune reactions directed against self by auto-reactive T cells and autoantibody-
producing B cells. How and why certain individuals get SS, and why some patients develop a 
more severe disease than others, remains to be further investigated. 
In the present study, minor salivary gland material and serum from patients with SS, 
and a relevant murine model have been investigated. An overall objective has been to 
determine clinicopathological features in human and murine disease with regard to 
organization of lymphoid tissue, and to explore possible strategies for detection of patients at 
increased risk for extra-glandular manifestations. 
 
 
GENERAL BACKGROUND 
Immunology of mucosa 
The immune system can be divided into various anatomical fields, out of which the two most 
important are the peripheral lymphatic system, consisting of the spleen and lymph nodes, and 
the mucosal immune system. The lymphocytes ability to recognize foreign antigens or 
substances sustains a separate entity of lymphocytes in each of these areas. The total mucosal 
area in the body, approximately 400 m2, is constantly subject to environmental triggers and 
therefore in need of an advanced innate (non-specific) and adaptive (specific) immune 
response. In contrast to the peripheral lymph nodes and blood, the type and distribution of T 
cells in the gut mucosa contains a large number of γδ T cells. Hence, the adaptive immune 
response in mucosa associated lymphoid tissue (MALT) differs from the rest of the peripheral 
lymphatic system (Janeway et al., 2005). 
The main type of antibody actively transported to the mucosal surface is the secretory 
polymeric IgA, with the two subclasses IgA1 and IgA2 in humans. The mucosal immune 
system is continuously exposed to a great number of foreign antigens from food, commensal 
bacteria in the gut and from pathogenic microorganisms and parasites. Food antigens do not 
normally elicit an immune response. Meanwhile, soluble antigens from the oral cavity may 
elicit antigen-specific tolerance or antigen-specific suppression, and pathogenic 
microorganisms may cause strongly preventive TH1 responses. Consequently, an important 
challenge for the immune system is to differentiate between these contradictions (Janeway et 
al., 2005). 
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The main difference between tolerance and an adaptive immune response in the 
mucosal immune system is determined by how peptide antigen is presented to T lymphocytes. 
In absence of inflammation, peptides are presented to T cells by MHC molecules on the 
surface of antigen-presenting cells (APCs) without co-stimulation. In the opposite situation, 
pathogenic microorganisms induce an inflammatory response in the tissue, stimulating 
maturation and expression of co-stimulatory molecules on the APCs. This form of antigen-
presentation to T cells contributes to the development of TH1 protection (Janeway et al., 
2005). 
 
Mediators of the immune system 
Cytokines 
Cytokines are small proteins (~ 25 kDa) secreted from many cell types as a response to an 
activating stimulus. Activation induces growth, differentiation and/or function, through 
binding to specific receptors. Cytokines may have an autocrine, paracrine or endocrine effect 
(Figure 1) and may have stimulatory/pro-inflammatory effects such as IL-1β, IL-6, GM-CSF 
and TNF-α, or inhibitory/anti-inflammatory effects, such as IL-4, TGF-β and IL-10. 
 
  
 
Figure 1. Activation induces a response in the cytokine-producing cell. Autocrine cytokines stimulate the same 
cell that synthesizes and secretes the cytokine, while paracrine cytokines act on cells in close proximity. Some 
cytokines may even have an endocrine effect, but this is strongly dependant on the cytokines ability to enter 
circulation, and the particular cytokines half time. 
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The term interleukin (IL) was suggested to provide a comprehensive nomenclature 
related to leukocytes. However, increasing numbers of novel cytokines of different sources, 
structures and effects, warranted for a more extensive system. Three larger, structural families 
now define cytokines, the haematopoietin family with growth hormones and many ILs with a 
role in both innate and adaptive immunity, the TNF family with functions in both adaptive 
and innate immunity, and the chemokine family (Janeway et al., 2005; Steinke and Borish, 
2006). 
Cytokines produced by T cells can currently be divided into three entities, the 
TH1, TH2 and TH3/TR1/T regulatory cells (Treg) (Figure 2). Cytokines produced by 
monocytes/macrophages as a response to pathogens, is a structurally derived group of 
molecules and include IL-1β, IL-6, IL-12, TNF-α and the chemokine CXCL8 (IL-8), 
reviewed in (Steinke and Borish, 2006). 
 
 
 
 
 
Figure 2. Cytokines produced by CD4 effector T cells. The differentiation into either an armed TH1 or TH2 cell 
determines whether the adaptive immune response will be dominated by macrophage activation (cellular 
immunity) or antibody production (humoral immunity). NK natural killer cell; M macrophage; MAST mast cell; 
Tc T cytotoxic cell. 
Chemokines 
Chemokines are a class of some 50 cytokines with chemo-attractive properties, the ability to 
induce cells with the appropriate chemokine-receptors to migrate in the direction of the source 
of the chemokine. In case of an infection, chemokines secreted from phagocytic cells recruit 
and direct monocytes, neutrophils and other effector cells to the site of antigenic stimulus 
(Janeway et al., 2005). The exact localization of the B cells, T cells and dendritic cells in 
peripheral lymphoid organs is conducted by chemokines (Cyster, 1999; Cyster, 2003). 
Chemokines can be divided into two major groups – the CC chemokines with two 
cysteins close to the amino terminal part, and CXC chemokines where the two cysteins are 
divided by another amino acid. CC chemokines (e.g. CCL21) bind to CC chemokine receptors 
(e.g. CCR7). CXC chemokines (e.g. CXCL13) bind to CXC receptors (e.g. CXCR5) 
(Janeway et al., 2005).  
 
Adhesion molecules 
The recruitment of effector cells during an inflammatory response is mediated by locally 
induced adhesion molecules on the surface of vascular endothelial cells and leukocytes. Three 
families of adhesion molecules, the selectins, intercellular adhesion molecules (ICAMs), and 
integrins, are important for the specific recruitment (homing) of leukocytes (Janeway et al., 
2005). 
Selectins are membrane glycoproteins with a distal lectin-like area which binds to 
specific carbohydrates. These adhesion molecules can be expressed on leukocytes (L-selectin) 
and vascular endothelium (P- and E-selectin), and are important for precise homing. L-
selectin is expressed on circulating T cells and guides their exit from the circulation into 
tissue. P- and E-selectin are induced on vascular endothelium at sites of infection and recruit 
effector cells to initiate endothelium-leukocyte interactions. In mucosal endothelium, L-
selectin binds to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), gaining entry 
into mucosal lymphoid tissues, while in lymph nodes, L-selectin binds to CD34 and 
(Glycosylation-dependent cell adhesion molecule-1) GlyCAM-1 (Janeway et al., 2005) 
(Figure 3). 
ICAMs such as ICAM and VCAM are members of the immunoglobulin super-family 
(IgSF), and mediate closer adhesion between endothelium and leukocytes. The IgSF also 
includes the antigen receptors of T and B cells, the co-receptors of CD4, CD8, and CD19, and 
the invariant domains of MHC molecules. Several of the IgSF members are important in T 
cell activation, such as ICAM-1-3 which all binds to the T cell integrin lymphocyte function-
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associated antigen-1 (LFA-1). ICAM-1 and ICAM-2 are expressed on endothelium as well as 
on APCs, enabling lymphocyte migration through blood vessels (Janeway et al., 2005). 
 
 
Figure 3. Possible mechanisms of inflammatory cell migration from the circulation into salivary gland tissue. 
Access is gained by crossing the walls of high endothelial venules/vascular endothelium. The first step is binding 
of L-selectin (on the lymphocyte) to MAdCAM-1 or CD34 on the endothelium, allowing a rolling interaction. 
Local expression of chemokine CXCL13 activates LFA-1 on the lymphocyte, allowing tight adhesion to ICAM-
1 on the endothelial cell, and the lymphocytes can migrate into the salivary gland tissue. Adapted and modified 
from (Janeway et al., 2005). 
 
Integrins are heterodimeric proteins on activated leukocytes. All T cells express the β2 
integrin, also known as LFA-1. In addition, LFA-1 is found on macrophages and neutrophils, 
mediating recruitment of inflammatory cells to sites of infection. Expression of integrin β1 
increases at late stages of T cell activation and is called very late activation antigens (VLA). 
VLAs are important in directing armed effector T cells to sites of inflammation. Depending 
on the type of adhesion molecules, cytokines and chemokines that are expressed, a selective 
and specific homing occurs (Janeway et al., 2005).
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Autoimmunity 
Autoimmune diseases are characterized by an abnormal state in which the immune system 
elicits an inflammatory response against the own cells, tissues and proteins. The direct 
mechanism behind autoimmunity remains undetermined, but several possibilities such as 
defects in the inflammatory cell control regime have been suggested. In addition, there also 
seems to be a familiar distribution of autoimmune diseases, suggesting genetic susceptibility 
(Bolstad and Jonsson, 2002; Kumar et al., 2003; Ollier and Symmons, 1992). 
 
Immunological tolerance 
Self-tolerance is the lack of immune-responsiveness to own tissues, and is regulated by 
central and peripheral tolerance (Figure 4). Central tolerance is the deletion of self-reactive T 
and B lymphocytes during maturation in central organs. For T cells this occurs in the thymus, 
and for B cells in the bone marrow. T cells expressing a receptor for self-antigen are 
negatively selected and deleted by apoptosis, resulting in a T cell pool depleted of auto-
reactive T cells. Unfortunately, not all self-antigens are present in the thymus, and auto-
reactive T cells may to some degree escape this control regime. Peripheral tolerance can be 
mediated by anergy, Fas/FasL mediated cell death, or suppression by Tregs (Kumar et al., 
2003). 
Anergy, functional unresponsiveness without cell death, is mediated by a prolonged or 
irreversible unresponsiveness of the lymphocyte. In order to become activated, T cells depend 
on two signals, the recognition of peptide antigen in association with self-MHC molecules on 
APCs, and the expression of co-stimulatory molecules, such as B7 molecules, provided by the 
APCs. If the second co-stimulatory signal is missing, the T cell becomes anergic, and will 
remain so even if the relevant antigen is presented by competent APCs and the appropriate co-
stimulation. Most normal tissues lack strong expression of co-stimulatory molecules, and 
encounter between auto-reactive T cells and their specific self-antigens frequently results in 
anergy (Kumar et al., 2003). 
B cells may also become anergic if they encounter antigen in absence of specific 
helper T cells. This kind of anergy is mediated by Fas and FasL. In cases where Fas and FasL 
are co-expressed on the same cohort of activated T cells, the immune response may be 
suppressed by apoptosis of these cells. In theory, activation-induced cell death may also cause 
peripheral deletion of auto-reactive T cells, wherein repeated and persistent stimulation of 
auto-reactive T cells by abundant self-antigens in the periphery eventually lead to their 
elimination via Fas-mediated apoptosis. 
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Figure 4. Mechanisms involved in central and peripheral tolerance of T cells, adapted from (Kumar et al., 2003).
 
The third means of peripheral self-tolerance is suppression by T regs, previously 
mentioned in the section on cytokines and Figure 2. By secretion of IL-10 and TGF-β, the 
CD4+CD25+ Tregs modulate a variety of responses to autoantigen, reviewed in (Steinke and 
Borish, 2006). Individuals lacking CD4+CD25+ T cells in the thymus develop autoimmune 
disease at a young age (Ramsdell, 2003). 
 
Mechanisms of autoimmunity 
Breakdown of one or more of the mechanisms of self-tolerance, as described above, can lead 
to an immunological attack on own tissues and eventually to the development of autoimmune 
diseases. Most likely the tissue injury is mediated by immunocompetent cells, but the precise 
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influences that cause the reaction against self are not known. Tolerance can be bypassed in a 
number of ways, and autoimmune diseases cannot be explained by one single mechanism. 
The defects vary from disease to disease, and more than one defect may be present in each 
disease. The breakdown of tolerance and initiation of autoimmunity involves a complex 
interaction of immunologic, genetic and microbial factors (Kumar et al., 2003). Possible 
etiological factors are summarized in Figure 5. 
 
Figure 5. Possible etiopathogenesis of autoimmune diseases. 
 
The clinical aspect of autoimmunity 
Autoimmune diseases may be restricted to specific organs of the body – organ-specific 
autoimmune diseases, or may affect several tissues – systemic autoimmune diseases. Organ-
specific autoimmune diseases may for instance affect the insulin-producing cells in the 
pancreas in Type I diabetes mellitus, the myelin sheath of nerves in multiple sclerosis (MS), 
or the red blood cells in autoimmune pernicious anemia (Figure 6). 
In systemic autoimmune diseases, the auto-antigen is a constituent of many organs, 
such as the synovium in rheumatoid arthritis (RA), connective tissue in scleroderma, DNA 
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and other nuclear components in systemic lupus erythematosus (SLE), or the salivary and 
lacrimal glands in primary SS (Figure 6). Systemic autoimmune disorders, such as RA, SS 
and SLE, have a number of autoantibodies and HLA haplotypes in common, reviewed in 
(Jonsson et al., 2005). 
Autoantibodies against receptors may also cause disease, by stimulating or blocking 
receptor function, such as antibodies targeting the acetylcholine receptors in myasthenia 
gravis (Vincent, 2002), and the M3R in SS (Waterman et al., 2000). 
 
 
 
 
 
 
 
Figure 6. Overview of various organ specific and 
non-organ specific (systemic) autoimmune 
diseases. Modified from (Ollier and Symmons, 
1992).
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SJÖGREN’S SYNDROME 
Disease manifestations 
Clincical symptoms 
Sjögren’s syndrome is an autoimmune chronic inflammatory disease which predominantly 
affects the salivary and lacrimal glands, giving rise to clinical symptoms such as oral and 
ocular dryness (xerostomia and keratoconjunctivitis sicca, respectively). SS predominantly 
affects post-menopausal women, in a 9:1 ratio compared to men. Younger individuals and 
children may also be affected (Jonsson et al., 2005). Common complaints are dryness of the 
mouth, difficulties to talk, taste and swallow (Abbas, 2005). In addition, patients with SS may 
also have signs of systemic autoimmune disease with musculoskeletal, pulmonary, gastric, 
hematological, dermatological, renal and neurological manifestations (Jonsson et al., 2005; 
Manthorpe et al., 1998). 
Patients with pSS have reduced secretion of saliva, higher dental caries activity, and 
lower salivary pH and buffer capacity compared to healthy controls (Pedersen et al., 2005). 
Interestingly, levels of potassium, total calcium, total protein and amylase activity in whole 
and parotid saliva, or the concentration of statherin and proline-rich proteins in stimulated 
parotid saliva did not differ from healthy controls. These findings indicate that despite 
lymphocytic infiltration and structural alterations within the salivary glands, the remaining 
secretory acini are indeed functional and capable of secreting saliva with normal composition 
(Mandel and Baurmash, 1976; Pedersen et al., 2005). 
Proteolytic activity of matrix metalloproteinases (MMPs) has been shown to be 
increased in pSS minor salivary glands (Goicovich et al., 2003; Perez et al., 2000), and may 
implicate structural changes in the glandular tissue and thus the quantity and quality of 
secreted mucins from these glands. The lack of mucins may offer an explanation to the 
sensation of dry mouth in the early stages of disease, where the submandibular and sublingual 
glands are more affected than the serous salivary glands (Atkinson, 1993; Lindvall and 
Jonsson, 1986). 
   
Histopathology of the target organ 
Histopathologically, SS is manifested by focal mononuclear inflammatory cell infiltrates of 
the affected organs, the salivary and lacrimal glands. The pathological designation is 
lymphoepithelial lesion (Seifert and Sobin, 1991). Intact acinar and ductal epithelium 
surrounds the lymphocytic infiltrates (Chisholm and Mason, 1968; Greenspan et al., 1974), 
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but acinar epithelial atrophy and proliferation of ductal epithelium may also be noted (Jonsson 
et al., 2005).  
Traditionally, the infiltrates are an accepted sign of the compromised salivary and 
lacrimal function (Figure 7), but a direct association between the degree of lymphoid 
infiltration and exocrine dysfunction is not always obvious (Humphreys-Beher et al., 1999). 
Immunohistochemical investigations have shown reduced density/lack of immune-reactive 
nerve fibers in the central areas of large lymphocytic infiltrates, while in the periphery, 
innervation is as abundant as in healthy controls (Fox and Stern, 2002; Pedersen et al., 2000), 
indicating that glandular atrophy and inflammation is a consequence of functional inhibition 
of the nervous control of the gland, rather than the reason for it.
 
Serology 
In a recent study, autoantibodies to the Ro/SSA and La/SSB protein were detected in 71% and 
56% of patients with pSS, Ro/SSA and La/SSB, respectively (Garberg et al., 2005). Although 
serum titers of Ro/SSA and La/SSB of the IgA isotype are reported to correlate with sicca 
symptoms (Pourmand et al., 1999), and hypergammaglobulinemia and persisting levels of 
autoantigen-specific IgM were demonstrated in patients with SS (Wahren et al., 1994a), the 
exact role of the Ro/SSA and La/SSB autoantibodies is not yet determined. Titres of SLE and 
RA associated autoantibdodies ANA and RF may also be elevated in SS, even in absence of 
another connective tissue disease (Jonsson et al., 2005).  
A variety of criteria have been proposed in the diagnosis of SS, such as the 
Californian/San Diego criteria (Fox et al., 1986), Greek criteria (Skopouli et al., 1986), the 
Japanese criteria (Homma et al., 1986), the Copenhagen criteria (Manthorpe et al., 1986), and 
the European criteria (Vitali et al., 1993). According to the American European Consensus 
group Criteria (AECC) (Vitali et al., 2002) applied in this study, the diagnosis of SS is based 
on four objective and two subjective items. At least four items must be fulfilled. One of these 
must be either focal periductal mononuclear cell infiltration, as demonstrated by light 
microscopy of H&E stained minor submucosal salivary gland biopsies, or the presence of 
serum autoantibodies to Ro/SSA and/or La/SSB (Figure 7). 
 
Etiology and pathogenesis 
Early inflammatory events  
Different factors such as Epstein-Barr virus (Wen et al., 1996) and coxsackievirus 
(Triantafyllopoulou and Moutsopoulos, 2005), certain HLA genes (Gottenberg et al., 2003; 
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Nakken et al., 2001) and influence of sex steroid hormones (Brennan et al., 2003) have been 
implied in the pathogenesis of SS. Transfer experiments suggested that SS is a T cell 
mediated disease (Skarstein et al., 1997), but recent findings indicate an associated homing of 
B cells, making up approximately 20% of infiltrating lymphocytes in the salivary glands 
(Jonsson et al., 2005; Larsson et al., 2005) (Figure 7). 
Epithelial cells produce several pro-inflammatory cytokines (Fox et al., 1994) and 
circulating levels of IL-1β, IL-12p40, TNF-α, and IL-6 were significantly different when 
comparing patients with SS to healthy controls (Szodoray et al., 2004) (Figure 7). The degree 
of glandular infiltration and glandular tissue destruction has been related to the expression of 
TH1 cytokines, whereas hyposalivation to some extent has been linked to humoral immune 
reactions promoted by TH2 cytokines (Mitsias et al., 2002).
Figure 7. Possible etiological factors of SS. Adapted from (Delaleu et al., 2004; Jonsson et al., 2005).
 
The homotypic adhesion between epithelial cells is, among others, mediated by the 
adhesion molecule E-cadherin. E-cadherin is the ligand of integrin αEβ7/CD103, which is 
normally expressed on CD8+ intraepithelial lymphocytes in the gut mucsoa (Cepek et al., 
1993; Cepek et al., 1994). The interaction between E-cadherin and αEβ7/CD103 may 
participate in the specific homing of inflammatory cells to the salivary glands (Figure 7). E-
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cadherin is also an important regulator of cell growth and mobility, tissue morphogenesis and 
apoptosis, during both embryogenesis and maturation, reviewed in (Gumbiner, 2000). 
The novel TNF family member B cell activating factor BAFF (also called BLyS, 
TALL-1, THANK, and zTNF4), A proliferation inducing ligand APRIL (also called TNFSF 
13a) and their receptors BAFF-R, BCMA and TACI (Gross et al., 2000; Moore et al., 1999; 
Mukhopadhyay et al., 1999; Schneider et al., 1999; Shu et al., 1999) have been investigated 
in order to determine their possible role in SS pathogenesis (Figure 8). BAFF contributes to 
disturbances in B cell survival, and this may contribute to autoimmunity and pathogenic 
autoantibodies (Mackay and Browning, 2002). 
 
 
Figure 8. Ligand specificity and function assignment of BAFF and APRIL receptors in the immune system. The 
interactions of BAFF and APRIL with their receptors (BAFF-R, BCMA and TACI) are shown in the upper part, 
and the phenotypic and functional outcomes of BAFF and/or APRIL signaling at the bottom. Colors indicate the 
tentative involvement of one or more receptors in mediating a particular effect. Figure adapted from (Schneider, 
2005).
Analyses of serum from patients with SS showed elevated levels of sBAFF (Pers et 
al., 2005), correlating with autoantibody levels (Groom et al., 2002; Mariette et al., 2003). 
BAFF expressing cells have been described in SS salivary glands (Lavie et al., 2004) and 
associated with attenuated apoptosis (Szodoray et al., 2003). Mice transgenic for BAFF 
develop SLE-like disease, followed by secondary SS-like disease (Groom et al., 2002). BAFF 
also plays a role in physiological processes but depending on the host, excess BAFF may 
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induce accumulation of self-reactive B cells by providing help to escape from BCR-mediated 
apoptosis (Mackay and Browning, 2002). 
 
Ectopic germinal centers 
Germinal centers are formed in the B cell follicles of secondary lymphoid tissues during T 
cell dependant antibody responses. Rapidly proliferating cells are called centroblasts and are 
localized in the dark zone of the GC. As the centroblasts mature they move into the light zone 
of the GC, and are now called centrocytes. In the light zone the centrocytes make contact with 
a rich network of follicular dendritic cells which present antigen to the centrocytes. Strict 
control regimes ensure that autoreactive cells die by apoptosis, and the surviving cells become 
either memory B cells or antibody-producing plasma cells (Janeway et al., 2005). Lymphoid 
neogenesis with formation of ectopic “tertiary” lymphoid follicles in chronic inflammatory 
diseases (Figure 9) is a complex process regulated by expression of an array of cytokines, 
chemokines and adhesion molecules (Hjelmström, 2001; Weyand and Goronzy, 2003). 
 
 
Figure 9. Three periductal inflammatory cell 
infiltrates: two focal infiltrates (FI) and one ectopic 
germinal center (GC) in a minor salivary gland 
from a patient with pSS. Note normal salivary 
gland tissue surrounding the inflammatory cell foci, 
and some adipose tissue. 
 
Lymphoid malignancy 
In SS, polyclonal B cell activation can develop into an oligo- or monoclonal B cell expansion 
during disease progression, potentially culminating in lymphoid malignancy, predominantly 
low-grade marginal zone (MZ) lymphomas (Theander et al., 2005; Voulgarelis et al., 1999). 
The incidence of lymphoma was reported higher in pSS than in sSS or RA (Kauppi et al., 
1997), and the estimated prevalence of malignant lymphoma in pSS was considered 44 times 
higher than in the general population (Voulgarelis et al., 1999), with a possible relation to 
ectopic GC formation (Amft and Bowman, 2001; Voulgarelis et al., 1999). In a more recent 
study, however, the risk of malignant transformation was found to be 16 times (Theander et 
al., 2005). 
FI 
FI  
GC
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Animal models of SS 
Clinical symptoms such as dry eyes and mouth appear rather late in SS pathogensis, making 
early diagnosis difficult. By use of animal models it is possible to study different stages of the 
disease development. Ideally, a model for SS should have oral and ocular dryness, chronic 
inflammation in the salivary and lacrimal glands, and systemic deviations such as 
hypergammaglobulinemia, antinuclear antibodies and autoantibodies to extractable nuclear 
antigens such as Ro/SSA and La/SSB. In the present study, the non-obese diabetic (NOD) 
mouse was selected and used to investigate chronological events in SS-like disease 
progression. 
 
NOD 
The NOD mouse is an animal model which spontaneously develops both autoimmune insulin-
dependant diabetes mellitus (IDDM) and SS. Progressive salivary gland inflammation may be 
noted as early as 8 weeks of age and is characterized by focal infiltrates of mononuclear cells. 
In addition, the NOD mouse has impaired salivary secretion from the major glands, a 
phenomenon which has not been observed in any other animal models for SS (Humphreys-
Beher et al., 2002; van Blokland and Versnel, 2002). 
NOD mice in which genes for various cytokines such as IL-4 and IFN-γ were knocked 
out have also been studied in relation to SS-like disease. NOD IL-4-/- have mononuclear cell 
infiltration, but normal salivary secretion (Brayer et al., 2001), while NOD IFN-γ-/- and NOD 
IFN-γR-/- have no infiltration and normal salivary secretion (Cha et al., 2004). Despite similar 
glandular infiltration compared to the NOD/LtJ or NOD.B10-H2b mice, the NOD.B10-
H2b.IL-4-/- and NOD IL-4-/- mice had comparable salivary secretion to 4 week-old mice of the 
same strain (Gao et al., 2006).  
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AIMS OF THE STUDY 
The general objective of this study was to determine clinicopathological features in human 
and murine disease with regard to organization of lymphoid tissue, and to explore possible 
strategies for detection of patients at increased risk for extra-glandular manifestations. 
 
 
The specific aims were 
I. To analyze the functional properties of ectopic germinal centers in SS and to 
determine at which frequency such structures develop 
 
II. To investigate the possible association between circulating levels of the novel TNF 
family members APRIL and BAFF and lymphoid organization in pSS 
 
III. To explore features of ectopic germinal centers in pSS, to determine if GC 
identified by phenotypic analysis correlate with morphological GC, and if such 
structures define a distinct clinical immunological phenotype 
 
IV. To determine serum levels of soluble E-cadherin (sE-cadherin) and to describe the 
expression of E-cadherin and αEβ7 on glandular epithelial cells and mononuclear 
cells in salivary gland epithelium in patients with SS 
 
V. To stratify the chronological disease course and characterize possible inter-
relationships between salivary gland inflammation, hyposalivation and cytokine 
levels in NOD mice, a model for SS 
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OVERVIEW OF PAPERS I-IV 
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MATERIALS AND METHODS 
Overviews of Papers I-V are illustrated on pp 23, 24 and 26. 
 
Human tissue material 
Patients and controls (Paper I-IV) 
Minor submucosal labial salivary glands and serum samples were obtained from patients 
fulfilling the revised American-European classification criteria (Vitali et al., 2002) for 
primary or secondary SS. Patients were recruited from the Departments of Rheumatology and 
Otolaryngology/Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway, 
from 1989-2005. Some of the minor salivary gland biopsy material had been divided in two 
portions. One portion was formalin fixed and used for routine histopathological evaluation, 
and the other portion transported in Histocon (HistoLab Products AB, Gothenburg, Sweden), 
and snap frozen in iso-pentane by liquid nitrogen and stored at -80°C. 
Medical records were obtained from all patients, dated as close to the time of the 
minor salivary gland biopsy as possible. For immunohistochemistry, normal controls 
consisted of individuals evaluated for SS presenting with subjective xerostomia but with 
sparse infiltration of mononuclear cells/absence of focal inflammation, negative serology, and 
normal salivary flow. The degree of inflammation had previously been determined by focus 
scoring of histological, formalin-fixed paraffin-embedded haematoxylin and eosin (H&E) 
stained sections, by an oral pathologist. Focus score denominates the number of focal 
mononuclear cell infiltrates (foci) of at least 50 mononuclear cells, per 4 mm2 (Chisholm and 
Mason, 1968; Greenspan et al., 1974). For the serological investigations, healthy age- and 
sex-matched blood donors served as controls. The studies were approved by the Committee of 
Ethics at the University of Bergen (145/96-44.96). 
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OVERVIEW OF PAPER V 
 
 
 
Murine tissue material 
NOD and Balb/c mice (Paper V) 
Female NOD and Balb/c mice were purchased from Taconic/Bomholtgård, Denmark. The 
animals were kept under standard animal housing conditions. Serum glucose levels were 
measured using Reflotron Plus Glucose test kit, Roche Diagnostics, Canada, and did not differ 
significantly between or within age-groups in NOD or Balb/c. NOD mice did not decrease in 
weight between 17 and 24 weeks of age. The experimental protocol was approved by the 
Committee for research on animals/Forsøksdyrutvalget (79-04/BBB). 
Stimulated salivary flow was investigated in all mice. Prior to stimulation, mice were 
fasted for a minimum of 5 hours with water ad libitum and anesthetized using 0.10 ml 
Ketalar/Domitor per 10 g bodyweight. Whole saliva was collected after stimulation of 
secretion by pilocarpine in saline (0.5 μg per gram bodyweight, Sigma Chemical Co, St 
Louis, MO, USA) administered via the femoral artery, to ensure reliable uptake. Saliva was 
collected with capillary tubes for 10 minutes, the volume determined, and stored at -80º C 
until analyzed. 
Salivary gland tissue was carefully dissected, kept on Histocon and snap-frozen as 
previously described. The tissue samples were cut by a cryostat, stained with H&E and then  
evaluated and morphometrically analyzed using a Leica DMLB light microscope connected to 
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a ColorView III-camera and AnalySIS® software (Soft Imaging System GmbH), to determine 
the focus score (Jonsson et al., 1987), i.e. the number of foci of 50 or more mononuclear cells 
per mm2 of glandular tissue, and the ratio of inflammation to the area of glandular tissue (ratio 
index) (Skarstein et al., 1997). Both glands were examined in at least two tissue sections. In 
the majority of cases, histomorphology and degree of inflammation was similar. In case of 
inconsistencies the tissue block was cut further down and new H&E sections evaluated. 
 
Immunohistochemistry 
Frozen tissue 
Avidin-Biotin-peroxidase Complex/ABC (Paper I, II, V) 
Briefly, frozen salivary gland tissue was cut (five μm sections) with a cryostat (Leica 
Instruments GmbH, Nussloch, Germany) onto APES treated glass slides. Following stepwise 
fixation in +4°C 50% acetone for 30 seconds and 100% acetone for 5 minutes, endogenous 
peroxidase was quenched with 0.3% H2O2 in TBS pH 7.6. To avoid background staining from 
endogenous biotin, sections were treated with Avidin D and Biotin blocking solution (Vector 
Laboratories, Burlingame, CA, USA) for 15 minutes each. Non-specific binding was blocked 
by incubation for 30 minutes with normal rabbit serum in antibody diluent. The sections were 
then incubated with the relevant primary antibody for 60 minutes. The appropriate 
biotinylated secondary antibody was applied for 30 minutes. Binding of secondary reagents 
was detected by incubation with Avidin-Biotin solution kit (5 μl Avidin DH + 5 μl Biotin 
Peroxidase in 625 μl TBS) for 60 minutes. 
Diaminobenzidine (DAB+) was used as chromogen. Sections were counterstained 
with haematoxylin and mounted with aqueous mounting medium (Thermo Shandon Immu-
mount, Pittsburgh, PA). Following incubations, sections were washed with TBS pH 7.6 for 2 
x 5 minutes. All procedures were performed at room temperature. Unless otherwise indicated, 
all materials were purchased from Dako A/S, Glostrup, Denmark. 
 
EnVision detection technique (Papers I-IV) 
After quenching of endogenous peroxidase activity (see above), sections were incubated with 
the appropriate primary antibody for 60 minutes and thereafter with EnVision+ (Dako A/S, 
Glostrup, Denmark), a horseradish peroxidase (HRP) and secondary antibody conjugated 
(dextrane) polymer, for 30 minutes. DAB+ was used as chromogen and remaining steps were 
similar to what is described for the ABC-method. 
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Immunostaining protocol with biotinylated antigens (Paper I) 
Recombinant proteins were expressed from the pMAL vector (New England Biolabs, 
Beverly, MA). Purification (Elagib et al., 1999), biotinylation of proteins and immunostaining 
were performed as previously described (Tengner et al., 1998). The recombinant fusion 
partner maltose binding protein (MaBP) was used in parallel. In short, endogenous 
peroxiadase, avidin and biotin activity were blocked as described above, and non-specific 
protein binding was blocked by 5% powdered milk and 4% bovine serum albumin (BSA) in 
TBS for 15 minutes. Sections were then incubated with biotin labelled Ro 52-kD protein, Ro 
60-kD protein, La protein, or MaBP for 45 minutes. Avidin and biotin–labelled HRP was 
used as secondary reagent and sections were incubated for 60 minutes. 3-amino-9-ethyl-
carbazole (AEC) was used as a substrate. Sections were counterstained with Harris’ 
hematoxylin. Following each step, except for the blocking step, the slides were rinsed and 
washed in TBS 2 x 5 minutes. 
 
Detection of apoptotic cells by in situ labelling using the TUNEL method (Paper I) 
DNA fragmentation during apoptosis was detected in situ by the TUNEL method as 
previously optimized (Ohlsson et al., 2001). Cryosections (5 μm) were dried and fixed with 
10% paraformaldehyde/phosphate buffered saline (PBS) for 30 minutes. Endogenous 
peroxidase was quenched by 0.1% H2O2 in TBS for 10 minutes. Sections were equilibrated in 
terminal deoxynucleotidyl transferase (TdT) buffer (0.5M cacodylate [pH 6.8], 1 mM CoCl2, 
0.5M dithiothreitol, 0.05% BSA, 0.15M NaCl) at 37°C and thereafter covered with TdT 
buffer containing 0.1 units/μl TdT (Boehringer, Mannheim, Germany) and 8 nmoles/ml 
digoxigenin-conjugated dUTP (Boehringer) in a humidified chamber for 60 minutes at 37°C. 
The reaction was stopped by washing in TBS supplemented with 5% fetal calf serum 
(FCS) followed by incubation with sheep anti-digoxigenin IgG (Boehringer) diluted to 5 
μg/ml in blocking solution for 60 minutes. After soaking in 10% pooled human sera, 5% 
rabbit sera, and 2% FCS in TBS, sections were incubated with HRP-conjugated rabbit anti-
sheep antibodies diluted 1:100 in blocking solution for 60 minutes. TUNEL-positive cells 
were visualized by incubation with AEC (see above) for 15 minutes, counterstained in Harris’ 
haematoxylin, and mounted as previously described. Between each step, sections were 
washed in TBS, and unless otherwise indicated all steps were carried out at room temperature. 
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Negative control tissue sections from each patient were incubated as described above, 
omitting dUTP. 
 
Double-labelling (Paper IV) 
Freshly cut sections of frozen minor salivary gland tissue were fixed as previously described. 
Sections were incubated with the first primary antibody for 60 minutes, followed by 
quenching of endogenous peroxidase by 0.03% H2O2 for 5 minutes. Thereafter, sections were 
incubated with Envision HRP for 30 minutes. DAB+ was used as a chromogen. Following a 5 
minute rinse in water, sections were incubated with Doublestain Block for 3 minutes. 
Incubation with the second primary antibody for 60 minutes was followed by incubation with 
Envision Alkaline-phosphatase for 30 minutes. After development with New Fuchsin for 12 
minutes or Liquid Permanent Red for 7 minutes, sections were counterstained with 
Haematoxylin, rinsed in tap water, and mounted with an aqueous mounting medium (see 
above). Between each step, sections were washed in TBS pH 7.6 for 10 minutes. Antibodies 
were diluted in antibody diluent. For comparison, serial sections were incubated separately 
with the two first primary antibodies. Unless otherwise indicated, all reagents were purchased 
from DAKO, Glostrup, Denmark. 
 
Formalin-fixed, paraffin-embedded tissue sections 
Heat induced antigen retrieval (Paper III) 
Paraffin-embedded salivary gland tissue was cut (4-6 μm sections) with a microtome (Leica 
Instruments GmbH, Nussloch, Germany) onto SuperFrost® Plus microscope slides (Menzel 
GmbH & Co KG, Braunschweig, Germany). Following step-wise de-paraffinization and re-
hydration by xylene and alcohol, heat-induced antigen retrieval (HIER) by use of Citrate 
buffer (S1699, Dako, Glostrup, Denmark) was performed. Quenching of endogenous 
peroxidase, incubations with primary antibodies and detection of antigen by the HRP-
conjugated EnVision+ detection system was employed (see above). Following counter-
staining by Haematoxylin, sections were de-hydrated and mounted with a non-aqueous 
mounting medium (Eukitt) prior to analysis. Except for the HIER, all incubations were 
performed in room temperature.  
 
 30
Double-labelling for CD21/CD23/CD35 and IgD (Paper III) 
To visualize the ectopic GC-formation, double-staining was performed. Briefly, paraffin-
embedded minor salivary gland tissue was cut and pre-treated as described above. Sections 
were incubated with monoclonal mouse anti-human CD21 (1:10), CD23 (1:5) or CD35 (1:5) 
for 60 minutes, followed by quenching of endogenous peroxidase for 5 minutes. Thereafter, 
sections were incubated with HRP-conjugated Envision for 40 minutes. DAB+ was used as a 
chromogen for 7 minutes. Following a 5 minute rinse in water, sections were incubated with 
Doublestain Block for 3 minutes. Incubation with the second primary antibody IgD (1:2.000) 
for 60 minutes at room temperature and over-night at 4ºC, was followed by incubation with 
Alkaline-phosphatase (AP)-conjugated Envision for 40 minutes. After development with 
Liquid Permanent Red for 7-10 minutes, sections were counterstained with haematoxylin, 
rinsed in tap water, and mounted with aqueous mounting medium. Between each step, 
sections were washed in TBS for 10 minutes. 
 
Evaluation of staining 
Between 3 and 6 minor salivary glands from each patient were evaluated in all stainings 
performed (Papers I-IV). Cells were counted using a light microscope with a grid and a 10x or 
40x objective. Positive cells were analyzed within 5-6 randomly selected fields across the 
whole section (both infiltrates and stroma). In specimens with fewer than 5 infiltrates, more 
than one area of infiltrating mononuclear cells within the same focal infiltrate was counted. 
For the adhesion molecules, cells with more than 50% of the cell membrane 
immunohistochemically stained quantified as positive. In quantifying TUNEL reactivity, only 
stained nucleus or nuclear fragments that morphologically matched apoptotic cells were 
counted as positive. Chemokines were mainly expressed by epithelial cells, and positive 
acinar and ductal epithelial cells in each glandular section were counted and expressed as the 
mean of 3–6 glands. 
In Paper II, the morphology of the salivary gland tissue infiltration could be divided 
into three units: GC, FI and scattered cells/small cell clusters in close relation to acinar or to 
ductal epithelium. Interstitial infiltration was also included in this paper, as these cells may 
participate directly in cell and tissue damage. Intensity of staining was not evaluated. For GC 
and FI the expression of CD4, CD8, CD20, CD35, CD38, CD68, Ki-67 and BAFF was 
evaluated as the percentage of positive infiltrating inflammatory cells of the total number of 
infiltrating inflammatory cells. Interstitially, the expression of immune reactive molecules 
was evaluated as the number of positive cells in close relation to acinar or ductal epithelium 
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of the total number of acinar or ductal epithelial cells, respectively, hereby providing a 
number for the density of the interstitial infiltration. 
In Paper III sections were evaluated based on the appearance of the FDC/B cell 
networks as presented by CD21, CD23 and CD35, and the distribution and pattern of the IgD 
staining within chronic inflammatory infiltrates. A scoring system for ectopic germinal center 
formation – GC-score, was defined. 
The staining-pattern of CD21, CD23 and CD35 within chronic inflammatory cell 
infiltrates, could be divided into six morphological entities numbered, each considered a 
progression of the previous. IgD positive cells were divided into three entities based on the 
density of the cell staining. The denomination obtained from the phenotypic staining pattern 
of CD21, CD23, CD35, and IgD was summarized and provided the basis for a “GC-score” 
ranging from 0-17. The 30% who presented with highest GC-score (cut-off > 12) were 
defined as GC+, and GC-score < 12 were defined as GC-. 
In Paper IV the expression of E-cadherin positive cells is presented as the percentage 
of E-cadherin positive ductal and acinar epithelial cells of the total number of ductal and 
acinar epithelial cells. The αEβ7/CD103 positive mononuclear cells are presented as the 
percentage of ductal or acinar units infiltrated by one or more αEβ7/CD103 positive cells and 
the total number of ductal or acinar units, respectively. 
 
Tissue controls 
In the human material (Papers I-IV) incubations with isotype and concentration matched 
controls were performed to ensure specific staining. Tonsil was used as the positive tissue 
control. Salivary gland tissue from patients evaluated for SS but not fulfilling the revised 
criteria (focus score < 1, negative serology and normal salivary flow) (Vitali et al., 2002) 
served as negative tissue controls (Papers I, II and IV). 
In the murine material (Paper V), incubations with antibody diluent was performed to 
ensure specific staining. Cervical lymph nodes served as the positive tissue control. Salivary 
gland tissue from age-matched control-mice (Balb/c) served as the negative tissue control. 
 
Enzyme linked immunosorbent assay – ELISA (Papers I, II, IV) 
Serum antibodies against Ro52, Ro60 and La (Paper I) were detected by an in-house ELISA 
as previously described (Elagib et al., 1999) with minor modifications. Commercial ELISA 
kits were used to detect soluble BAFF and APRIL (Paper II) and E-cadherin (Paper IV) in 
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serum samples form patients with pSS, and healthy controls. All analyzes were performed 
according to the manufacturer’s instructions. 
 
Cytokine measurements in serum and saliva (Paper V) 
Serum and saliva was analyzed using a mouse cytokine ten-plex assay kit (Catalog No 
LMC0001, BioSource, Nivelles, Belgium), as recommended by the manufacturer, measured 
on a Luminex 100 (Luminex Corp, Austin, Texas, USA) and analyzed using StarSection 
software (Applied Cytometry Systems, Dinnington, UK). Mean values of cytokines IL-1β, IL-
2, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN-γ and TNF-α present at detectable levels 
were compared between the different age-groups of mice, and to the age-matched controls. 
 
Statistical analyses 
Paper I: Statistical analysis. The Mann-Whitney test was used for statistical analysis of 
nonparametric data. The Spearman correlation coefficient was calculated for testing 
correlation of parameters. Chi-square analysis was employed for comparing GC occurrence in 
primary and secondary SS. P-values less than 0.05 were considered statistically significant. 
 
Paper II: Statistical analyses were performed using the Mann–Whitney test for non-
parametric data. Correlation was investigated using Pearson’s correlation co-efficient. A p-
value of p < 0.05 was considered statistically significant. 
 
Paper III: Data were frequently not normally distributed. The Mann-Whitney test was used to 
study differences between groups and Spearman correlation for relationships between 
variables. Chi-square analysis was employed for categorical data. 
 
Paper IV: Statistical analyses were performed using the Mann–Whitney test for non-
parametric data. Correlation was investigated using Pearson’s correlation co-efficient. A p-
value of p < 0.05 was considered statistically significant. 
 
Paper V: Statistical analyzes were performed using 1-way Anova followed by Bonferroni 
post-test for selected groups (modified unpaired two-tailed student’s t-test optimized for 
multiple group comparison). To determine the linear relationship between two variables, 
values were compared using Pearson’s correlation test (two-tailed). 
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Statistical analyses in Papers I-IV were preformed using SPSS 13.0 and GraphPad Prism 4.0 
in Paper V. 
 
Methodological considerations 
Minor salivary gland tissue samples 
The tissue sections described in Papers I-IV were obtained from patients under investigation 
for SS at the Department of Rheumatology between 1991 and 2002 (Paper I, n=165), 1989 
and 2003 (Paper II, only pSS, n=130), 1989 and 2005 (Paper III, n=272), and 1991 and 2004 
(Paper IV, n=27). 
  n GC+ (%) Paraffin (P) / Frozen (F) 
Paper I  165 28 (17)  
 pSS 91 19 (21) F (n=14) 
 sSS 50 7 (14) F (n=5) 
 FS 24 2 (8)  
Paper II pSS 130 33 (25) F (n=37)* 
Paper III  272 59 (22)  
 pSS 169 47 (28) P (n=60) 
 sSS 38 6 (16)  
 FS 65 6 (9)  
Paper IV  27* 22  
 pSS 22 12 F (n=22)* 
 sSS 5 3 F (n=5)* 
*partially overlapping with Paper I, supplemental frozen salivary gland tissue added 
 
Routine histopathological assessment for focal inflammation was performed at the 
Department of Oral Sciences – Oral pathology and Forensic Odontology and/or the Gade 
Institute – Department of Pathology. The morphological screening for GC-like features was 
performed by MVJ on the H&E stained paraffin embedded material. In Papers I, II and IV, 
immunohistochemical investigations were performed on frozen material from tissue sampled 
at the same time as the paraffin embedded material diagnosis was based on. As a result, 
similar inflammation and/or morphology may not have been present in the frozen as in the 
paraffin, and vice versa. There is some overlap concerning frozen minor salivary gland tissue 
used in Paper I, II and IV, but inflammation and morphology may have changed as the tissue 
was cut down. In Paper III, immunohistochemical investigations were performed on the same 
tissue blocks as had been used in the diagnostics, i.e inflammation and morphology was the 
most similar to the diagnostic background. As could be expected, however, the morphology of 
these sections changed as well, as a result of being cut down. 
In addition, to obtain staining on paraffin embedded material, heat-induced epitope-
retrieval was detrimental. Staining is highly dependant on the fixation of tissue (Hayat, 2002). 
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Frozen tissue was transported in Histocon prior to snap-freezing by iso-pentane and storage in 
-80°C. Cut sections were stained within three weeks in order not to lose antigen expression. 
Frozen tissue sections were stored at -80°C and cut paraffin sections at 4°C. 
 
Detection method – EnVision and ABC 
When applicable, an EnVision based staining system was utilized in favour of the traditional 
AvidinBiotinComplex method (Jordan et al., 2002; Marthinussen et al., 2002; Sabattini et al., 
1998; Vyberg et al., 2005). The EnVision technique is based on a polymer back-bone 
conjugated with both secondary antibodies and enzyme (HRP or AP). Several secondary 
antibodies on the same backbone makes EnVision more sensitive than the ABC method, and 
it is possible to use higher dilutions of the primary antibody. In addition, the EnVision system 
does not contain biotin, which is an advantage when working with salivary glands where 
endogenous biotin may give rise to unwanted background staining. Finally, since the 
secondary antibody and enzyme are applied simultaneously, the protocol is less time-
consuming. Unfortunately, the EnVision system is limited to antibodies made in mouse or 
rabbit. 
 
Substrate – AEC and DAB+ 
For most of the immunohistochemical staining, DAB+ was selected before AEC, because 
DAB+, in our hands, was considered more reactive. The combination of EnVision+ and 
DAB+ provides an increase in sensitivity and specificity (Marthinussen et al., 2002). 
 
Statistical considerations (Paper V) 
To determine if the means between age-groups of NOD and Balb/c mice, or between NOD 
and age-matched controls differed significantly, all data was analyzed using 1-way Anova 
followed by Bonferroni post-test for selected groups (modified unpaired two-tailed student’s 
t-test optimized for multiple group comparison). To normalize skewed distributions, cytokine 
data was log-transformed prior to all statistical analyses. Correlation analyses were restricted 
to NOD and to datasets where a scientific reason for a causal connection was given from 
either our results or from previous studies.
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SUMMARY OF RESULTS 
 
Paper I 
GC-like structures were observed in 28 of 165 patients (17%). When GC were defined as T 
and B cell aggregates, with proliferating cells, a network of follicular dendritic cells, and 
activated endothelial cells, such microenvironments were found in all patients in whom 
structures with GC-like morphology were observed. The defined microenvironments were not 
found in patients without apparent GC-like structures in the H&E routine biopsy. The GC 
formed within the target tissue showed functional features with production of autoantibodies 
(anti-Ro/SSA and anti-La/SSB) and apoptotic events (by TUNEL staining), and the local 
production of anti-Ro/SSA and anti-La/SSB autoantibodies was significantly increased (P = 
0.04) in patients with GC development. 
 
Paper II 
The B cell related molecules B cell activating factor (BAFF) and a proliferation-inducing 
ligand (APRIL) are members of the tumour necrosis factor super-family. Circulating levels of 
BAFF and APRIL were investigated in relation to serological deviations and lymphoid 
organization in the salivary glands of SS. Lymphoid organization in the shape of ectopic 
germinal centers were detected in 33 of 130 consecutive minor salivary gland biopsies and 
coincided with increased focus score and elevated levels of serum IgG. Follicular dendritic 
cell networks, significantly increased levels of proliferating cells, increased numbers of B 
cells and reduced numbers of T cells were detected in GC compared to FI, both when 
comparing within and between GC+ and GC- glands. BAFF+ cells were detected in similar 
levels in GC and FI. Interestingly, CD38+ plasma cells were detected in the periphery of GC, 
albeit at reduced numbers compared to the FI, where plasma cells appeared scattered within 
the whole infiltrate. 
 
Paper III 
Retrospectively, minor salivary gland biopsies (n=272) with focal lymphoid aggregates 
corresponding to focus score > 1 were evaluated for the presence of GC-like morphology. 
Randomly selected biopsies from patients with pSS (n=60) were further investigated by 
immunohistochemistry. Based on the reticular network staining-pattern of CD21, CD23 and 
CD35, and the distribution of IgD positive cells, a GC-score was constructed and biopsies 
characterized as GC+ or GC-. Relevant clinical information was obtained from medical 
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records. 169/272 patients fulfilled the American-European criteria for pSS (Vitali et al., 
2002). The remaining either fulfilled criteria for sSS, or records were not accessible and it was 
not possible to ascertain either pSS or sSS. By morphology, GC-like features were observed 
in 47/169 (28%) biopsies. By immunohistochemistry, ectopic follicles/GC were determined in 
18/60 (30%) patients, compared to 11/60 (18%) by the original morphological screening of 
this random cohort. Morphological and phenotypic GC corresponded in 5/11 biopsies. 
Irrespective of method to detect GC, mean inflammatory focus score was significantly 
increased in GC+ compared to GC- (p<0.05), and elevated titers of rheumatoid factor, serum 
autoantibodies and IgG levels were more common in GC+. 
 
Paper IV 
Serum levels of sE-cadherin were significantly increased in SS compared to non-SS and non-
significantly in GC+ compared to GC– patients. Membrane-bound E-cadherin was detected 
on the majority of acinar and ductal epithelial cells in both SS and non-SS. αEβ7/CD103-
positive cells were found scattered in focal infiltrates and GC, and in small clusters close to 
ductal and acinar epithelium at an increased level in SS compared to non-SS. Interestingly, E-
cadherin-positive cells were detected randomly dispersed in focal lymphocytic infiltrates in 
10/21 patients. By double-labelling, the mononuclear cells with the E-cadherin-positive 
component were identified as CD68+ macrophages. 
 
Paper V 
Female NOD mice of different age-groups were used to mimic different disease-stages of SS. 
Histopathology and cellular composition were compared in 8-, 17- and 24-week old female 
mice. In addition, cytokines were analyzed in serum and saliva, and compared to age-matched 
controls. Salivary flow remained unchanged when comparing 8- and 17-week old NOD mice, 
while a significant decrease took place between 17 and 24 weeks (p<0.001). In contrast, the 
significant changes in histopathology of the salivary glands occurred before 17 weeks of age. 
Immunohistochemical analyses revealed changes in inflammatory cell organization in the 
salivary glands, resembling ectopic germinal centers. Regarding cytokines, significant 
differences were detected in serum levels of IL-2, IL-5 and GM-CSF, and IL-4 and TNF-α in 
saliva. Correlation analyses revealed a negative association between salivary secretion and 
IFN-γ and TNF-α levels in saliva. Association of these cytokines in relation to 
histopathological changes was consistently weak.
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GENERAL DISCUSSION 
Recruitment of inflammatory cells in SS – attraction and retention 
Chronic inflammation in the form of a designated lymphoepithelial lesion (Seifert and Sobin, 
1991) is an important issue in the diagnostics of SS (Vitali et al., 2002). From a pathological 
point of view, the histopathological aspect of SS is based on the presence of focal 
mononuclear cell infiltrates consisting of at least 50 cells per 4 mm2 minor salivary gland 
tissue (Chisholm and Mason, 1968; Greenspan et al., 1974). In approximately 1/4th of patients 
with SS we have discovered GC-like formations within otherwise normal salivary gland 
tissue. These structures were linked to increased attraction and retention of chronic 
inflammatory cells and local autoantibody production (Paper I), B cell activation and disease 
progression (Paper II) and a distinct seroimmunologcial profile characterized by increased 
IgG, RF and autoantbodies (Paper III). 
The inflammatory cell foci interact with the surrounding epithelium as well as 
contribute to the progressive inflammation, by synthesis and expression of various cytokines, 
chemokines and adhesion molecules, reviewed in (Delaleu et al., 2004). In chronic 
inflammatory sites, cells are prevented from dying and leaving the inflamed tissue, a result of 
inappropriate expression of pro-survival and pro-retention signals by stromal elements. 
Fibroblasts represent such stromal elements in RA (Buckley et al., 2001; Buckley, 2003). In 
SS, salivary gland epithelium may represent such stromal elements (Figure 10). 
Chemokines choreograph the positioning of cells during an immune response. We 
have investigated local factors mediating attraction and retention of chronic inflammatory 
cells, by chemokines CXCL12, CXCL13 and CCL21, and by adhesion molecules ICAM-
1/LFA-1 and VCAM-1/VLA-1 (Paper I). The CXCL12-CXCR4 interaction was previously 
investigated in RA, enabling a switch from migratory to stationary phenotype as leukocytes 
enter tissue microenvironments, reviewed in (Buckley, 2003). CXCL13 and its receptor 
CXCR5 has previously been investigated in chronic inflammatory cell infiltrates in salivary 
glands of patients with SS (Amft et al., 2001; Salomonsson et al., 2002; Xanthou et al., 2001) 
and RA (Burman et al., 2005; Schmutz et al., 2005; Shi et al., 2001; Takemura et al., 2001). 
The migration of naïve and activated T cells into lymphoid tissues is mediated by the 
chemokine SLC/CCL21, expressed on HEVs, stromal cells and dendritic cells in lymphoid 
tissue, and binds to the CCR7 chemokine receptor on naïve T cells (Buckley, 2003). We have 
detected high expression of CCL21 (Paper I) in chronic inflammatory cell infiltrates in SS, 
indicating that SS is a result of increased lymphocyte entry to the salivary glands. Interstingly, 
CCR7 has also been ascribed in T lymphocyte exit from peripheral tissues such as skin 
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(Debes et al., 2005). The occurrence of CCR7 was investigated in peripheral blood B cells in 
pSS {Hansen, 2005 #351} but no significant differences were detected compared to healthy 
controls. All the same, it is tempting to speculate whether CCR7 expression is altered or 
impaired upon contact/interaction with salivary gland tissue stroma. 
Recent findings indicate that CXCR3, the target of CXCL10, CXCL11 and CXCL19, 
acts as a chemokine scavenging receptor in normal salivary gland epithelial cells. In salivary 
gland epithelium from patients with SS, however, the function of CXCR3 was impaired, 
possibly favouring chemotaxis and increased recruitment of T lymphocytes expressing 
CXCR3 (Sfriso et al., 2006). 
 
  
 
Figure 10. Homeostasis is maintained during a 
normal inflammatory reaction (A). Cell 
accumulation in an organ depends on the balance of 
cell attraction, division (proliferation), emigration 
and death (apoptosis). In order for the immune 
reaction to resolve, recruited cells must either die 
by apoptosis or exit via lymphatic vessels. In a 
chronic inflammatory reaction (B), local pro-
retentive and pro-survival factors (cytokines and 
chemokines) produced by salivary gland epithelial 
cells or inflammatory cells, influence the local 
environment and cause inappropriate accumulation 
of cells. Adapted and modified from (Buckley et 
al., 2001).
 
In NOD mice the attraction and retention of lymphocytes in lacrimal glands depended 
on expression of integrin αEβ1, L-selectin, and LFA-1 expression on lymphocytes, and 
VCAM-1 and peripheral node addressin (PNAd) on endothelial cells (Mikulowska-Mennis et 
al., 2001). We have detected increased levels of αEβ7/CD103+ cells in close relation to E-
cadherin+ epithelial cells in the salivary glands of patients with SS. This issue will be further 
discussed in the section on Epithelial cell adhesion molecules in SS (Paper IV). In contrast, 
migration to the lacrimal glands seemed to occur independently of MAdCAM and α4β7 
(Mikulowska-Mennis et al., 2001). However, these data were based on findings in mice and 
in lacrimal glands, and in human salivary gland tissue or intestinal mucosa, the situation may 
be different. 
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Local and systemic autoantibody production 
Although the exact role and function of the autoantigen and Ro/SSA and La/SSB 
autoantibodies are not yet determined, positive serology of Ro/SSA and La/SSB are 
associated features of SS (Vitali et al., 2002). Local autoantibody production has been 
described by immunohistochemistry in the salivary glands of patients with SS (Salomonsson 
and Wahren-Herlenius, 2003; Tengner et al., 1998) and was demonstrated in association with 
GC-like structures in the salivary glands from patients with SS (Paper I). Autoantibody 
producing cells may also reside in other tissues, as demonstrated in the thymus and lymph 
nodes in addition to salivary glands of sero-positive MRL/lpr mice (Wahren et al., 1994b). 
In addition to serum and salivary glands, autoantibodies have also been detected in 
saliva (Horsfall et al., 1989) and ectopic GC-formation with autoantibody production in the 
salivary glands was thus implicated in the pathogenesis of SS. When the immune system fails 
to create an efficient immune response against a highly localized antigen, it may prove 
advantageous to move the lymphoid tissue to the target of the inflammatory response, in SS 
the salivary glands, as will be further discussed in the section on Clinical implications of 
ectopic GC formation. 
In Paper I, the autoantibody-producing cells were located in the margin of large 
infiltrates/GC, as well as interstitially. In correlation, CD38+ plasma cells were detected in the 
periphery of large infiltrates, as well as in cellular accumulations in the salivary gland 
interstitial area (Paper II). The local production of anti-Ro/SSA and anti-La/SSB in the 
salivary glands was associated with higher levels of autoantibodies in sera (Paper I). Although 
absolute titres of Ro/SSA and La/SSB were not determined in Paper II and Paper III, a higher 
frequency of patients with ectopic GC were seropositive for anti-Ro/SSA and/or anti-La/SSB, 
confirming findings in Paper I. 
Autoantibody-producing cells in large infiltrates were also in part related to apoptotic 
events, identified by the TUNEL method as previously described (Ohlsson et al., 2001). In 
accordance to previous findings, moderate levels of apoptotic cells were detected (Ohlsson et 
al., 2001), somewhat more frequently in the GC+ compared to the GC- salivary glands (Paper 
I). These findings indicate an attenuation or escape from apoptosis (Ohlsson et al., 2002) 
possibly mediated by BAFF (Szodoray et al., 2003). 
 
B cell activation and germinal center formation in SS 
Germinal center formation was investigated in more detail (Paper II), and the contemporary 
existence of GC and FI was disclosed. GC were characterized by B and T cell organization, 
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increased levels of proliferating cells, follicular dendritic cell networks and the localization of 
plasma cells in a mantel zone-like area. Antigen-presenting cells in the focal infiltrates and 
germinal centers indicate ongoing antigen-presentation (Paper II and IV). BAFF was 
expressed on inflammatory cells scattered in both GC and FI, but no particular staining 
pattern could be determined for the two entities.
BAFF-expressing cells are considered important in the pathogenesis of pSS and have 
previously been linked to attenuated apoptosis (Groom et al., 2002; Lavie et al., 2004; 
Szodoray et al., 2003). The attenuation of apoptosis induced by excess levels of BAFF has 
been suggested to contribute to progression of disease (Mackay and Browning, 2002). The 
expression of BAFF was comparable in GC and FI, showing a membrane-bound staining on 
scattered infiltrating cells. Serum levels of sBAFF were increased in pSS, but similar in 
GC+ and GC- patients (Paper II). This observation indicates that BAFF is not fundamental for 
the GC-formation, confirming findings in BAFF knock-out mice (Vora et al., 2003). 
Increased serum levels of sBAFF compared to healthy donors reflect an ideal environment for 
B cell activation, wherein excess levels of BAFF may “tip the scale” in favour of auto-
reactive B cells, supplying them with various survival factors (Figure 11). Elevated levels of 
sBAFF have also been described to correlate with serum levels of autoantibodies in pSS 
(Groom et al., 2002; Mariette et al., 2003), although we could only detect a slight increase of 
sBAFF in the anti-Ro/SSA/La/SSB+ patients (Paper II). 
 
 
 
Figure 11. The balance between B cell death and survival is modified by signals generated by interactions 
between BCR and BAFF–BAFF-R. Physiological levels of BAFF in the presence of low-affinity BCR signals 
lead to cell maturation, while the encounter of BCR with antigen in physiological circumstances and normal 
BAFF levels leads to negative selection. Increased BAFF production favours B cell survival, promoted by 
induction of anti-apoptotic pathways such as Bcl-2 and Bcl-XL. Figure modified from (Mackay and Browning, 
2002). 
Inflammatory cells expressing BAFF were detected in close relation to acinar 
epithelium in both GC+ and GC- patients, indicating that although ectopic GC-formation in 
pSS occurs independently of BAFF, BAFF may still play a role in the initiation and 
establishment of chronic inflammatory cell infiltrates. These data were further supported by 
the correlation between increased levels of sBAFF and increased focus score in the GC+ 
patients (Paper II). No significant correlations were detected in GC- patients. The response of 
infiltrating B cells to BAFF may be modified by various cytokines (Szodoray et al., 2005) and 
this may differ in GC+ and GC- patients. 
Salivary gland epithelial cells stimulated by IFN-α and INF-γ are reported to secrete 
BAFF (Ittah et al., 2006). Type I interferons were recently implicated in the pathogenesis of 
SS (Hjelmervik et al., 2005), wherein IFN-α promotes the autoimmune process with 
increased autoantibody production and formation of endogenous IFN-α inducers (Båve et al., 
2005) and IFN-γ is reported to inducing expression of T cell attracting chemokine I-
TAC/CXCL11 in ductal salivary gland epithelium (Ogawa et al., 2004). Interestingly, TNF-α 
in combination with IFN-γ was the strongest stimulatory agent for secretion of BAFF by 
salivary gland epithelial cells (Ittah et al., 2006). 
APRIL has previously been reported to have a possible role in T-independent type II 
antigen responses and T cell survival, but also to induce proliferation/survival of non-
lymphoid cells (Mackay and Ambrose, 2003). Interestingly, a correlation was noted between 
focus score, serum levels of IgG and increased levels of sAPRIL, and sAPRIL levels were 
significantly increased in the Ro/SSA/La/SSB+ patients with pSS (Paper II). Salivary gland 
epithelium showed a cytoplasmic staining of APRIL (authors’ own unpublished 
observations). 
 
Clinical implications of ectopic germinal center formation? 
In Paper III, all the investigated patients with pSS (n=169) fulfilled the revised European 
criteria of 2002 (Vitali et al., 2002). By morphology, GC-like structures were detected in 
47/169 of patients. Focus score, IgG levels and RF titres were elevated compared to the GC- 
patients. In the randomly selected cohort (n=60), eleven patients had morphological GC. 
Morphological GC were ascertained by the CD21/CD23/CD35 phenotype in 5/11 biopsies. If 
taking morphology into account, this number increased to 7/11. Autoantibodies to Ro/SSA 
and La/SSB were also more common in GC+ compared to GC- (Paper III). However, sero-
positivity for anti-Ro/SSA or anti-La/SSB does not directly implicate disease, as indicated by 
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a recent report wherein 12/100 healthy blood donors had auto-reactive Ro-52 and 15/100 had 
auto-reactive La-48 (Garberg et al., 2005). 
Mean un-stimulated salivary flow was reduced in the GC+ patients (Paper III). 
Previous reports indicate that the submandibular and sublingual salivary glands are most 
severely affected in SS (Lindvall and Jonsson, 1986). As a result, the lubricating saliva from 
these glands is the first that is lost, while the watery, protein-rich parotid saliva remains 
seemingly unaffected. Consequently, total salivary secretion can therefore be within normal 
values, while un-stimulated, resting saliva is affected, giving a low secretion rate. On the 
other hand, it is debated how objective and reliable the un-stimulated salivary secretion 
measurement is, and how the un-stimulated secretion from the parotid gland compares to the 
submandibular and sublingual glands (Atkinson et al., 1990; Atkinson, 1993; Lindvall and 
Jonsson, 1986). 
It is speculated whether the chronic inflammation in the salivary glands in SS is a 
result of chronic inflammation resulting from retained factors in saliva, or antigen in the 
salivary gland tissue. Focal infiltrates develop surrounding the ducts, indicating that the ducts 
either contain chronic triggers, the ductal epithelial cells function as APCs, or the the situation 
is similar to the tonsil/lymph node where antigen enters the lymphoid tissue via the 
epithelium. Nevertheless, autoimmune diseases are considered the result of a multi-step 
process wherein genetic and environmental factors interact over a long period of time. 
Lymphoid neogenesis within the salivary glands in SS may be a result of chronic local stress, 
or indeed an important aspect in the chronic nature of the autoimmune response, imposing a 
possible risk for immune recognition and breakdown of self-tolerance per se (Figure 12). 
An association of GC development with increased risk of B cell lymphomas has been 
proposed (Voulgarelis et al., 1999), wherein formation of proliferating GC were thought to 
contribute to malignant transformation and development of MALT lymphoma (Figure 12). 
The estimated life-time risk of lymphoma in SS has been estimated to be 5-10% (Ioannidis et 
al., 2002; Voulgarelis et al., 1999), but in general mortality is not significantly increased 
compared to the general population (Theander et al., 2004). Patients with SS and chronic 
Helicobacter pylori infection are at increased risk for developing lymphomas, possibly related 
to prolonged lymphocytic activation in the target organ(s) of these patients (Raderer et al., 
2001; Streubel et al., 2004). In a recent study, significant predictors of lymphoproliferative 
disease were purpura/skin vasculitis, low levels of complement factors C3/C4, CD4+ T-
lymphocytopenia and a low CD4+/CD8+ T-cell ratio (Ioannidis et al., 2002; Theander et al., 
2005). Unfortunately, data on C3/C4 levels was only available in 50/165 patients (Paper III). 
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Figure 12. Chronic inflammation in the salivary glands may induce formation of ectopic lymphoid tissue. 
Hypothetical steps leading to development of GC in salivary gland tissue are illustrated above. Activated T cells, 
B cells and DC are detected in the salivary and lacrimal glands and preferentially accumulate around ductal 
epithelium. Activated lymphocytes induce a change of stromal cells into FDCs that produce CXCL13 and 
CXCL12 leading to attraction of CXCR5 and CXCR4-expressing B and T cells, respectively. Organized 
aggregates composed of B cells and a network of functionally mature FDCs form and a GC develop. T cells and 
plasma cells are present at the periphery of the follicle. Long-term, inappropriate cytokine production may lead 
to prolonged BAFF expression/secretion, in turn possibly promoting illegitimate DNA recombinations and 
somatic mutations that contribute to neoplastic transformations, reviewed in (Szodoray and Jonsson, 2005). 
Figure adapted from (Uccelli et al., 2005) and modified. 
 
B cell dysfunction (d'Arbonneau et al., 2006) and disturbances of B cell maturation 
(Bohnhorst et al., 2001; Bohnhorst et al., 2002) have been demonstrated in patients with SS, 
implying that over-stimulation and neglected selection may take place in induced GC in the 
affected glands. In accordance, formation of ectopic lymphoid microstructures in non-
lymphoid organs participate in the pathogenesis of organ-specific autoimmune reactions and 
underscore an essential role for the target organ in inflammatory cell recruitment and disease 
progression (Paper I-III). Despite inconclusive findings regarding the C3/C4 levels in the 
present pSS cohort, results from Paper III indicate a certain clinical immunological phenotype 
for SS patients with ectopic lymphoid organization, which warrant further prospective studies. 
Whether ectopic GC identifies patients at risk remains to be seen in prospective studies. 
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Epithelial cell adhesion molecules in SS 
E-cadherin is expressed by epithelial cells and infiltrating cells in both germinal centers and 
focal infiltrates, mediating homo- and heterotypic adhesion between epithelial cells 
(Gumbiner, 1996) and αEβ7/CD103+ T lymphocytes (Cepek et al., 1994). Altered E-cadherin 
staining patterns are related to malignant transformation of various cancers, to both metastasis 
and invasive growth (Davies et al., 2001; Noë et al., 2001). Soluble E-cadherin (sE-cadherin) 
has, among others, previously been investigated in relation to systemic inflammatory 
responses (Pittard et al., 1996) and as a pre-therapeutic factor for survival in gastric cancer 
(Chan et al., 2001; Chan et al., 2003). 
The majority of salivary gland epithelial cells expressed E-cadherin. An interesting 
finding was the observation of E-cadherin positive cells within chronic inflammatory cell 
infiltrates, as previously described in major salivary glands from NOD mice (Esch et al., 
2000). By co-staining, the E-cadherin+ infiltrating cells were identified as CD68+ 
macrophages (Paper IV). 
Clusters of αEβ7/CD103 positive cells were located nearby and occasionally 
infiltrated E-cadherin expressing ductal and acinar epithelium at significantly increased levels 
in SS compared to non-SS individuals. These findings and the positive correlation of 
infiltrated acini and disease progression (focus score) suggest a role for the αEβ7/CD103 and 
E-cadherin interaction in early homing and retention of inflammatory cells in the salivary 
glands in SS. 
In contrast to previous findings (Fujihara et al., 1999; Kroneld et al., 1998) our study 
demonstrated αEβ7/CD103 positive cells in various lymphocytic infiltration (GC and FI) and 
in relation to salivary gland acinar and ductal epithelium from non-SS individuals as well. 
Fujihara et al did not detect αEβ7/CD103 on lymphocytes adhering to acinar epithelium in 
any of the non-SS lacrimal glands (Fujihara et al., 1999), while Kroneld et al detected 
αEβ7/CD103 positive cells in 90% of the SS salivary glands investigated (Kroneld et al., 
1998). Factors such as fixation/preparation of tissue specimens, detection methods and 
substrate may affect the expression and possibility to detect antigen, as considered in the 
Materials and Methods section. 
Elevated serum levels of sE-cadherin were detected in patients with SS, and indicate 
increased epithelial tissue turnover, possibly related to ongoing tissue regeneration induced by 
chronic inflammatory changes in the exocrine glands, but a relationship with the expression of 
membrane-bound E-cadherin on salivary gland epithelial cells could not be detected. Most 
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likely, the soluble peptide fragment (80 kDa) detected as sE-cadherin is a degradation product 
of membrane-bound E-cadherin, generated by a Ca2+ dependent proteolytic action. In vitro 
experiments indicate that MMPs matrilysin and stromelysin-1 cleave E-cadherin at the cell 
surface, and that the released fragment inhibits E-cadherin functions in a paracrine way (Noë 
et al., 2001). MMPs have previously been described in glandular destruction in SS (Perez et 
al., 2000) by disturbing the extra-cellular matrix (Goicovich et al., 2003). 
Serum levels of sE-cadherin were further studied in regard to a potential non-invasive 
indicator of SS. Other chronic inflammatory diseases such as oral lichen planus (OLP), and 
RA were included as controls. Serum levels of sE-cadherin were found to be significantly 
increased compared to healthy donors, but not compared to patients with OLP or RA. 
Interestingly, one of the highest levels of sE-cadherin measured was in one of the blood 
donors (authors’ own unpublished, preliminary observations). 
In comparison to other studies, our assay (Paper V) was purchased from R&D Systems 
(www.rndsystems.com), and has a different standard/detection limit from the Zymed assay 
(www.invitrogen.com) used by others (Chan et al., 2001; Chan et al., 2003). Similar trends 
were noted, but limited the possibility to at least quantitatively compare one study to another. 
 
SS pathogenesis in the NOD mouse 
Chronic inflammation and hyposalivation 
In NOD major salivary glands, we further investigated cellular composition and lymphoid 
organization of the chronic inflammatory cell infiltrates. Interestingly, distinct B and T cell 
areas, and proliferating cells were detected in 4/12 glands from mice > 17 weeks of age (Paper 
V). These findings indicate that in some mice proliferation of inflammatory cells, in addition 
to attraction and retention (homing), contributes to the progression of disease. This has 
previously been suggested in RA synovium (Weyand and Goronzy, 2003) and human minor 
salivary glands (Amft et al., 2001; Stott et al., 1998; Xanthou et al., 2001) but to our 
knowledge not been described in NOD salivary glands. As observed in human minor salivary 
glands (Papers I-III), proliferating cells were associated with progression of disease (higher 
focus score) compared to litter-mates/peers. No differences in cytokine levels were observed 
when comparing NOD mice with or without proliferating inflammatory cells in the salivary 
glands (unpublished data from paper V). The significance of proliferating cells within chronic 
inflammatory cell infiltrates remains unknown, but may be related to increased B cell activity 
and survival, as discussed in Paper II. 
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It has long been debated when the (clinical) loss of salivary secretion occurs and how 
it is mediated, what comes first and what is the link between glandular inflammation and 
hyposalivation. Possible suggestions include autoantibodies to the M3R (Waterman et al., 
2000) and/or influence of the innervation (Rosignoli et al., 2005). NOD IL-4-/- develop focal 
inflammation but no loss of salivary secretion unless there is a transfer of T cells, indicating 
the importance of T and B cells interactions. Following transfer, anti-M3R antibodies can be 
detected (Brayer et al., 2001; Gao et al., 2006). Systemic and local production of anti-Ro-52 
has been described in MRL/lpr (Wahren et al., 1994b) but reports on the occurrence of anti-
Ro and anti-La in NOD are limited (Skarstein et al., 1995) and anti-Ro-52-positivity in serum 
did not seem to be related to the inflammatory component. In the NOD mice we observed, 
loss of secretory function occurred late in the disease course, between 17-24 weeks of age. 
 
Cytokines in serum and saliva 
Protein levels of cytokines were measured in serum and saliva. IL-2, IL-5 and GM-CSF 
presented with the most interesting findings in serum, and IL-4, TNF-α and IFN-γ in saliva 
(Paper V). These changes in cytokine levels indicate a role for the adaptive immune response 
in progression of disease. 
However, immunological reactions unrelated to the SS-like disease may influence the 
salivary gland inflammation, hyposalivation and cytokine production, and the NOD strain 
must be considered a model of general as well as specific immune dysregulation. A major 
draw-back of using NOD mice to mimic SS is the concomitant development of IDDM – it is 
not possible to determine whether pathology in the salivary glands is related to the IDDM or 
the SS-pathogenesis. The mice investigated (Paper V) were purchased from Taconic, and are 
not used as often as mice obtained from Jackson laboratories, but we believe that the NOD 
mice in our setting were suitable to model SS. All mice showed characteristic inflammatory 
changes in the salivary glands, and a significant decrease in salivary secretion compared to 
younger peers and age-matched Balb/c. In addition to supplier, stalling conditions may 
influence how prone the mice are to actually develop IDDM – the cleaner facilities, the higher 
incidence of diabetes. 
IL-2 is a TH2 cytokine which has been reported to play an important role in 
maintaining natural immunological self-tolerance by promoting growth and suppressor 
functions of regulatory T cells. Neutralization of circulating IL-2 aggravated diverse 
autoimmune manifestations (Setoguchi et al., 2005). Recent research indicates that absence of 
IL-5, another TH2 cytokine, can induce a shift towards adaptive immune responses. However, 
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the observed decrease of serum IL-5 (Paper V) is difficult to interpret because little is known 
about the role of IL-5 in SS. Increased levels of IL-4 in saliva (Paper V) further implied a 
function of the adaptive immune system. The negative association between IL-4 and salivary 
secretion are in conformity with findings in NOD.B10-H2b.IL-4-/- mice which develop focal 
salivary gland inflammation but no loss of salivary secretion (Gao et al., 2006). IFN-γ and IL-
4 are suggested to antagonize the development of TH-17 cells (Figure 13), triggering pro-
inflammatory responses in autoimmune disease and causing destructive tissue pathology 
(Harrington et al., 2005; Park et al., 2005; Wynn, 2005). In accordance, NOD.B10-H2b.IL-4-/- 
and NOD IL-4-/- both develop SS-like disease in the salivary glands (Brayer et al., 2001; Gao 
et al., 2006). NOD IFN-γ-/- and NOD IFN-γR-/- do not display SS-like pathology in the 
salivary glands, and have normal salivary secretion (Cha et al., 2004). 
 
 
 
Figure 13. IL-17 acts in cellular immunity. The TH-17 cells are regarded as a potent pro-inflammatory mediator 
linked to autoimmune and inflammatory diseases, reviewed in (Kolls and Lindén, 2004), and has recently been 
suggested to be a separate and early lineage of effector CD4+ TH cells (Harrington et al., 2005; Park et al., 
2005).  IL-17 can induce expression of a range of cytokines and chemokines on epithelial cells and vascular 
endothelial cells, such as IL-6, GM-CSF and CXCL10, and neutrophil-activating IL-6 and CXCL8 (IL-8) 
secretion by fibroblasts (Steinke and Borish, 2006). Development of IL-17 producing effector CD4+ T cells (TH-
17) by IL-23 is inhibited by IFN-γ and IL-4. Figure adapted from (Wynn, 2005).
 
GM-CSF is a major regulator of granulocytes and macrophages, and a recent report 
indicate a role of GM-CSF in inflammation and autoimmunity (Hamilton, 2002). From in 
vitro studies, tissue neutrophil recruitment through the induction of GM-CSF and IL-8 
indicate a pro-inflammatory role of IL-17 (Kolls and Lindén, 2004). TNF-α is one of the 
cytokines capable of inducing GM-CSF production (Leizer et al., 1990) and interestingly, 
overt stage of disease in NOD was associated with increased saliva levels of TNF-α (Paper 
V). Little is known on the role of GM-CSF in SS, whereas TNF-α is known to have a wide 
spectrum of biological activities (Janeway et al., 2005). Amongst other, TNF-α is considered 
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an essential cytokine in the pathogenesis of rheumatic diseases, and  anti-TNF-α therapies 
were successfully introduced in the treatment of RA (Feldmann, 2002). Initial results in 
treatment of SS were encouraging (Steinfeld et al., 2002). Unfortunately, subsequent clinical 
trials failed to confirm these findings (Mariette et al., 2004; Sankar et al., 2004). Autoimmune 
and inflammatory disorders may be more efficiently treated by targeting the activity of TH-17 
rather than TH1 or TH2 cells. 
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CONCLUSIONS 
 
In analogy with the proposed specific aims, the following conclusions can be drawn: 
 
• Ectopic germinal centers are formed in approximately 25% of patients with pSS 
• Ectopic GC formation is characterized by increased levels of local and systemic 
autoantibody production (Ro/SSA, La/SSB and RF), higher degree of inflammation 
(focus score) and increased serum levels of IgG 
• Soluble E-cadherin is increased in SS compared to non-SS and may be a result of, or 
an initiating/contributing factor to the chronic inflammation 
• In NOD mice, focal sialadenitis precedes hyposalivation, and the loss of salivary 
secretion is not accompanied by a change in inflammation 
• 30% of NOD mice have proliferating cells in the focal infiltrates and these mice have 
more inflammation (higher focus score) than their peers/littermates 
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FUTURE PROSPECTIVES 
SS is a slowly progressive disease with immunological and clinical implications. Ideally, 
treatment of a disease should inhibit, or at least prevent progression of disease. At present a 
number of factors counteract this possibility in SS: 1) initiating factor(s) remain(s) obscure, 2) 
clinical symptoms develop late and 3) there are no tests for early detection of SS. 
Pharmacological inhibitors currently available either target other diseases, or have severe 
side-effects and restricted to the really sick patients. Until the initiating factor in SS is known, 
and can be “eliminated” treatment should relief symptoms and inhibit, or at least interfere 
with and modify the pathological gathering of activated T and B cells (Figure 14). 
 
 
 
Figure 14. Summary of pathogenic events illustrating possibilities for immune-targeting. As a response to a yet 
unknown stimulus, salivary gland epithelial cells produce pro-inflammatory cytokines and chemoattractive and 
retentive chemokines which activate adhesion molecules on salivary gland endothelium and inflammatory cells 
(Paper I and V). Entrance of inflammatory cells into the target tissue microenvironment most likely alters or 
modifies both the inflammatory cells, and the target tissue. Reduced apoptosis/increased cell survival is, among 
others, mediated by BAFF (Paper II). BAFF expression and secretion by salivary gland epithelial cells can be 
induced by Type I interferons. Serum IL-2 and IL-5, and saliva IL-4, TNF-α and IFN-γ were related to disease 
progression (Paper V). Reduced exit, possibly resulting from impaired CCR7 signaling, further leads to 
accumulation of activated T and B cells and ultimately GC-formation with increased local and systemic 
autoantibody production (Paper I-III), isotype switching and possibly lymphomagenesis. Shedding of epithelial 
cells and E-cadherin most likely occurs as a result of MMP-mediated tissue destruction (Paper IV) and offer a 
potential tool for early detection of SS.
 
In Crohns disease, MS, RA and atherosclerosis, a monoclonal antibody targeting 
integrin VLA-4/α4β1, an antisense inhibitor of VCAM-1 and a probucol derivative of ICAM-
1 are under development, reviewed in (Delaleu et al., 2004). Treatment targeting BAFF in 
SLE is under development (Baker et al., 2003). Recent findings indicate an additive role of 
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TNF-α and IFN-γ in inducing BAFF-expression in SS salivary gland epithelium (Ittah et al., 
2006), and as discussed above, initial results concerning anti-TNF-α treatment in SS were 
promising (Steinfeld et al., 2002), but could not be confirmed (Mariette et al., 2004; Sankar et 
al., 2004). Indeed, a combination therapy – a cocktail – of several cytokine inhibitors may 
provide the solution? 
Initital results targeting B cells by anti-CD20 monoclonal antibodies showed clinical 
improvement in a few cases of patients with SS presenting with MZ or non-Hodgkins 
lymphoma (Voulgarelis et al., 2004), and a recent case-report indicated improvement of both 
clinical symptoms and histopathological changes (Pijpe et al., 2005b), confirmed by an open-
label Phase II study concluded that Rituximab is effective in the treatment of SS (Pijpe et al., 
2005a). Patients with ectopic GC have increased B cell activity, and may represent a target 
group in such trials, supporting the attempt in this thesis to sub-categorize patients with pSS. 
Multiple cellular responses initiate events that under normal conditions lead to 
resolution of the inflammatory reaction (Han and Ulevitch, 2005). Thus, breakdown in the 
regulation of an inflammatory response results in chronic inflammation (Figure 14). Future 
treatment should aim to inhibit tissue-specific inflammation by regional delivery and without 
interfering with the migration and function of leukocytes in protective immunity (Luster et al., 
2005). 
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